Business Wire

Dole Food Company Releases 2020 Corporate Responsibility & Sustainability Report

22.4.2020 16:00:00 EEST | Business Wire | Press release

Share

Dole Food Company announced today the release of its 2020 Corporate Responsibility & Sustainability Report. The report unveils the organization’s new sustainability framework, “The Dole Way,” along with the company’s first-ever enterprise-wide sustainability goals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005205/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dole Fresh Fruit, Pineapple Farm (Photo: Business Wire)

“Since our founding, Dole has strived to deliver the best of which we are capable—in both our products and how we produce them,” stated Johan Linden, CEO of Dole. “The need for healthy food choices has never been more evident than during these past weeks as we adapt under this global pandemic. The journey and dedication to be a responsible citizen of our communities as well as a good steward of our land will continue into our future and Dole will remain steadfast in being honest and transparent about our efforts and our impacts in supplying wholesome food across the globe.”

“Of course,” Linden continued, “our stakeholders expect this of us, but even more we expect this of ourselves; to engage in open dialogue, including critical voices, to make a measurable and meaningful difference for people and the planet, and to constantly evaluate and improve. It’s what we believe is the right way to do business.”

Dole’s sustainability report outlines an ambitious slate of initiatives under the Dole Way framework focused on tangible action directed towards five key goals:

  • More than ever, Dole understands our responsibility to positively impact underserved communities and promises to donate no less that 2,500 tons of fresh fruit and produce by 2025.
  • Dole will effect valuable long-term change by declaring a social premium for Dole branded bananas and pineapple. This social investment will be directed by company organizations and independent foundations that have operated in Dole’s Latin American production areas for decades and will be invested in the communities according to local needs.
  • Dole produce is grown in areas where water is becoming increasingly scarce, and Dole is committed to reduce water usage while improving water quality in its operations.
  • Dole will continue to take action to promote healthy eating and nutrition education, with a special focus on youth. At its core, this is a promise to support people living longer and healthier lives.
  • Dole recognizes that climate change is real and that the food and agriculture industries have a role to play in mitigating its effects. Dole will focus on decreasing its carbon footprint by ensuring new vessels include efficiency upgrades and working towards achieving net zero carbon emissions at farm level by 2030.

Other important sustainability targets include ensuring all packaging materials used in Dole’s banana and pineapple businesses are either recyclable or compostable by 2025, and introducing blockchain or similar technology in all operations to bring about a step-change in food safety and transparency.

Reporting on the impacts of Dole’s responsibility and sustainability goals is also of critical importance.

“This report and our goals are a new milestone in our sustainability pursuit, and farming is at the heart of that transformation. As farmers, we are facing the reality of climate change and are joining all other concerned people and businesses willing to tackle this challenge in our supply chain,” said Xavier Roussel, Vice President of Sustainability. “We will build on our learning—both in precision farming and organic agriculture—to deliver on our commitments in alliance with our business partners and other stakeholders. As an employer we will continue to make a difference in the lives of our employees and local communities and make a positive impact both within our farm borders and beyond.”

Added Roussel, “Dole is absolutely committed to being part of the community of concerned citizens taking on the sustainability challenge.”

To view all Dole’s achievements and goals click the link to the 2020 Corporate Responsibility & Sustainability Report click here.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye